ANSTO LifeSciences, Australian Nuclear Science and Technology Organisation, Locked bag 2001, Kirrawee DC, 2232, NSW, Australia,
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):138-51. doi: 10.1007/s00259-014-2895-3. Epub 2014 Sep 18.
The in vivo binding parameters of the novel imidazopyridine TSPO ligand [(18)F]PBR102 were assessed and compared with those of [(18)F]PBR111 in a rodent model of neuroinflammation. The validity of the key assumptions of the simplified reference tissue model (SRTM) for estimation of binding potential (BP) was determined, with validation against a two-tissue compartment model (2TC).
Acute neuroinflammation was assessed 7 days after unilateral stereotaxic administration of (R,S)-α-amino-3-hydroxy-5-methyl-4-isoxazolopropionique (AMPA) in anaesthetized adult Wistar rats. Anaesthetized rats were implanted with a femoral arterial cannula then injected with a low mass of [(18)F]PBR102 or [(18)F]PBR111 and dynamic images were acquired over 60 min using an INVEON PET/CT camera. Another population of rats underwent the same PET protocol after pretreatment with a presaturating mass of the same unlabelled tracer (1 mg/kg) to assess the validity of the reference region for SRTM analysis. Arterial blood was sampled during imaging, allowing pharmacokinetic determination of radiotracer concentrations. Plasma activity concentration-time curves were corrected for unchanged tracer based on metabolic characterization experiments in a separate cohort of Wistar rats. The stability of neuroinflammation in both imaging cohorts was assessed by [(125)I] CLINDE TSPO quantitative autoradiography, OX42/GFAP immunohistochemistry, Fluoro-Jade C histology, and elemental mapping using microparticle-induced x-ray emission spectroscopy. The BP of each ligand were assessed in the two cohorts of lesioned animals using both SRTM and a 2TC with arterial parent compound concentration, coupled with the results from the presaturation cohort for comparison and validation of the SRTM.
The BPs of [(18)F]PBR102 [(18)F]PBR111 were equivalent, with improved signal-to-noise ratio and sensitivity compared with [(11)C]PK11195. The presaturation study showed differences in the volume of distribution between the ipsilateral striatum and the striatum contralateral to the injury (0.7) indicating that an assumption of the SRTM was not met. The modelling indicated that the BPs were consistent for both ligands. Between the SRTM and 2TC model, the BPs were highly correlated, but there was a bias in BP.
[(18)F]PBR102 and [(18)F]PBR111 have equivalent binding properties in vivo, displaying significantly greater BPs with lower signal-to-noise ratio than [(11)C]PK11195. While an assumption of the SRTM was not met, this modelling approach was validated against 2TC modelling for both ligands, facilitating future use in longitudinal PET imaging of neuroinflammation.
评估新型咪唑并吡啶 TSPO 配体 [(18)F]PBR102 的体内结合参数,并与 [(18)F]PBR111 在神经炎症的啮齿动物模型中进行比较。确定简化参考组织模型(SRTM)用于估计结合潜力(BP)的关键假设的有效性,并通过与双组织隔室模型(2TC)进行验证。
在麻醉的成年 Wistar 大鼠单侧立体定向给予 (R,S)-α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)后 7 天评估急性神经炎症。麻醉大鼠植入股动脉插管,然后注射低质量的 [(18)F]PBR102 或 [(18)F]PBR111,并使用 INVEON PET/CT 相机在 60 分钟内采集动态图像。另一组大鼠在预处理后用相同的未标记示踪剂(1mg/kg)的预饱和质量进行相同的 PET 方案,以评估 SRTM 分析的参考区域的有效性。在成像过程中采集动脉血样,允许放射性示踪剂浓度的药代动力学测定。根据在单独一组 Wistar 大鼠中进行的代谢特征实验,对血浆活性浓度-时间曲线进行了基于未改变示踪剂的校正。使用微粒子诱导 X 射线发射光谱法,通过 [(125)I]CLINDE TSPO 定量放射自显影术、OX42/GFAP 免疫组织化学、Fluoro-Jade C 组织学和元素映射来评估两个成像队列中神经炎症的稳定性。使用 SRTM 和 2TC 结合动脉母体化合物浓度,结合预饱和队列的结果,在两个损伤动物队列中评估每个配体的 BP,用于比较和验证 SRTM。
[(18)F]PBR102 [(18)F]PBR111 的 BP 相当,与 [(11)C]PK11195 相比,具有更高的信噪比和灵敏度。预饱和研究表明,损伤对侧纹状体和同侧纹状体之间的分布容积存在差异(0.7),表明 SRTM 的一个假设不成立。模型表明,两种配体的 BP 一致。在 SRTM 和 2TC 模型之间,BP 高度相关,但存在 BP 偏差。
[(18)F]PBR102 和 [(18)F]PBR111 在体内具有相当的结合特性,与 [(11)C]PK11195 相比,显示出显著更高的 BP 和更低的信噪比。虽然 SRTM 的一个假设不成立,但这种建模方法已针对两种配体进行了 2TC 建模的验证,为神经炎症的纵向 PET 成像的未来应用提供了便利。